Form D · Other

Cellix Biosciences, Inc.

Newark, NJ · CIK 0001772419

Offering snapshot reported Mar 18, 2021 · SEC filing

Reported sold
$1.49M
Offering amount: $3M
Investors reported
8
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Mar 20, 2019
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$745K$1.49MApr 2, 2019: $500,000.00Apr 2, 2019Mar 18, 2021: $1,490,000.00Mar 18, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$500,000 → $1,490,000
  • Reported investors2 → 8

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Mar 18, 2021Amendment$1,490,000$990,000vs Apr 2, 20198SEC filing
Apr 2, 2019Initial$500,000No comparison2SEC filing

Offering details

Securities
Debt, Option to acquire
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-336224

Source: Form D, filed Mar 18, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Subramaniam Apparsundaram Director, Executive, Promoter
Mahesh Kandula Director
Jaideep Khanna Director

Issuer details

Industry: Other (See others in industry)

Address:
Njit Edc Building #524 211 Warren Street
Newark, NJ, 07103